Researchers at The Institute of Cancer Research in London have recently employed hormone therapy in their most recent trials to suppress the G9a enzyme, which catalyses H3K9me2, thereby preventing cancer cells from going into dormancy as a result of epigenetic modifications [169]. Here, EHMT2 is linked to cancer.